New drug combo aims to stall prostate cancer in chinese men

NCT ID NCT05171387

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, potentially slowing tumor growth. Researchers will measure how well the treatment lowers PSA levels, a marker of cancer activity, and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: darolutamide
What this could lead to: If successful, this could confirm darolutamide as an effective treatment option for Chinese men with this type of prostate cancer, potentially slowing disease progression.
What could go wrong: This is a Phase 2 study with a small number of participants, so results may not be conclusive. Side effects from darolutamide or hormone therapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Many Locations

Multiple Locations, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.